Navigation Links
Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
Date:10/25/2007

LOD, Israel, October 25 /PRNewswire/ -- Glycominds Ltd., a bio-diagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today entering into a research agreement with Fox Chase Cancer Center (FCCC), an NCI designated cancer center to develop a new diagnostics blood test for breast cancer.

"We are very pleased to work with FCCC on this project," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP R&D. "Glycominds' anti-glycan antibodies biomarkers approach together with the FCCC excellent patient records, samples and clinical know-how give this project a high basis for success."

"Glycominds' glycan biomarker technology stands out as innovative and unique. We hope that just as Glycominds was able to successfully develop new diagnostic and prognostic biomarkers for Autoimmune disorders, we will be able to identify glycans that can be useful in the early detection of cancer," stated Dr. Andrew K. Godwin, FCCC's Director of the Clinical Molecular Genetics Laboratory and the Biosample Repository . "I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer and improve the health and quality of life for millions of women."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers. http://www.glycominds.com

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: +1-646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: +1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Purchase of Madison broadband network may bring improved service
2. Wisconsin fares slightly better in venture capital chase
3. Metavante completes purchase of check processing firm
4. Logicalis purchases Solution Technology for $90M
5. Merge eFilm announces stock repurchase plan
6. Wisconsin based Graphics Distribution, Inc. purchased by Florida company
7. GE Medicals Acquisitions May Prompt More Purchases
8. Green Bay Software Company Purchased by GE
9. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
10. Cancer siRNA Oligo Set Version 1.0
11. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has announced ... their offering. ... biopolymers market to grow at a CAGR of 16.83% during the period ... growth prospects of the global biopolymers market for 2017-2021. To calculate the ... sales of biopolymer products. The report also includes a a discussion of ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in ... its customers three new solutions for measurements where traditional cuvette applications are not ... customer has an oddly-shaped sample that would not fit into a typical cuvette ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... devices with short response times capable of performing routine electrochemical biosensing has ... screen-printed electrodes provide fast, sensitive detection and quantification of various analytes in ...
(Date:1/12/2017)... , January 12, 2017 ... the world,s biggest facility for producing mycorrhizae. The Centre ... nutrient tapping potential of mycorrhizae and developed a technology ... ... http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility has ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
Breaking Biology News(10 mins):